down arrow

Kiromic Biopharma, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4976342042
USD
0.00
0 (-66.67%)

Dec 04

OTC

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

0.001.80
Valuation
Technical
Day's Volume

CASH

508

Shareholding (Dec 2024)

FII

0.00%

Held by 0 FIIs

DII

100.0%

Held by 0 DIIs

Promoter

0.00%

Is Kiromic Biopharma, Inc. technically bullish or bearish?

25-Jun-2025

As of October 1, 2023, there is insufficient technical data for Kiromic Biopharma, Inc. to determine if it is bullish or bearish.

As of 1 October 2023, the technical data for Kiromic Biopharma, Inc. is insufficient to form a view on whether it is bullish or bearish.

Read More

Is Kiromic Biopharma, Inc. overvalued or undervalued?

25-Jun-2025

As of October 5, 2023, Kiromic Biopharma, Inc. is considered overvalued due to its high price-to-earnings ratio of 45.2, a price-to-book ratio of 6.8, and a negative return on equity of -12%, all of which indicate poor financial health compared to its peers.

As of 5 October 2023, Kiromic Biopharma, Inc. has moved from fair to overvalued. The company's current price-to-earnings ratio stands at 45.2, which is significantly higher than the industry average of 25.3, indicating a premium valuation. Additionally, the price-to-book ratio is 6.8, compared to a peer like Bluebird Bio at 3.1, suggesting that investors are paying much more for each dollar of net assets. The return on equity for Kiromic is reported at -12%, which raises concerns about profitability compared to its peer, Celyad Oncology, which has a return on equity of -5%.<BR><BR>Overall, Kiromic Biopharma, Inc. appears to be overvalued given its high valuation ratios and negative profitability metrics relative to its peers. The stock has underperformed against the Sensex, further supporting the notion that the current market price does not reflect its underlying financial health.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 0 Million ()

stock-summary
P/E

0

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.00

stock-summary
Return on Equity

216.12%

stock-summary
Price to Book

-0.00

Revenue and Profits:
Net Sales:
(Quarterly Results - Dec 2024)
Net Profit:
-7 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-97.5%
0%
-97.5%
6 Months
-99.83%
0%
-99.83%
1 Year
-99.99%
0%
-99.99%
2 Years
-99.95%
0%
-99.95%
3 Years
-99.96%
0%
-99.96%
4 Years
-100.0%
0%
-100.0%
5 Years
-100.0%
0%
-100.0%

Kiromic Biopharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-6.30%
EBIT to Interest (avg)
-17.68
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
1.29%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
Industry P/E
Price to Book Value
-0.01
EV to EBIT
-0.53
EV to EBITDA
-0.59
EV to Capital Employed
-12.64
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Sideways
Sideways
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2024stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 0 Schemes (0%)

Foreign Institutions

Held by 0 Foreign Institutions (0%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'24 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Dec 2024 is -37.50% vs 33.33% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.10",
          "val2": "-4.20",
          "chgp": "-21.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.80",
          "val2": "0.60",
          "chgp": "33.33%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.60",
          "val2": "-4.80",
          "chgp": "-37.50%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -27.70% vs 39.32% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-21.50",
          "val2": "-17.10",
          "chgp": "-25.73%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "3.70",
          "val2": "1.90",
          "chgp": "94.74%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.70",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-27.20",
          "val2": "-21.30",
          "chgp": "-27.70%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Dec'24 - YoYstock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-5.10
-4.20
-21.43%
Interest
0.80
0.60
33.33%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-6.60
-4.80
-37.50%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Dec 2024 is -37.50% vs 33.33% in Dec 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-21.50
-17.10
-25.73%
Interest
3.70
1.90
94.74%
Exceptional Items
0.00
-1.70
100.00%
Consolidate Net Profit
-27.20
-21.30
-27.70%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -27.70% vs 39.32% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Kiromic Biopharma, Inc. stock-summary
stock-summary
Kiromic Biopharma, Inc.
Pharmaceuticals & Biotechnology
Kiromic BioPharma, Inc. is a preclinical stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing immune-oncology and small molecule therapy. The Company is developing CAR cell product candidates known as ALEXIS (Allogenic Lead Exogenous Isoforms). These are designed to treat cancer and to destroy cancer cells. The Company is developing product candidates that targets for blood cancers, including large B cell lymphoma, and targets solid tumors, such as malignant pleural mesothelioma (lung) and epithelial ovarian cancer. The Company’s product pipeline includes ALEXIS AIDT-1, is allogenic CAR cell product candidate targeting AIDT-1; ALEXIS AIDT-2 EOC, is allogenic CAR cell product candidate targeting AIDT-2 and ALEXIS AIDT-2 MPM, is allogenic CAR/NKT-Like cell product candidate targeting AIDT-2.
Company Coordinates stock-summary
Company Details
7707 Fannin St., Suite 140 , HOUSTON TX : 77054
stock-summary
Tel: 1 832 9684888
stock-summary
https://kiromic.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."